MetLife Investment Management’s Korro Bio KRRO Stock Holding History

MetLife Investment Management’s Portfolio KRRO Stock Details KRRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-3,945	Closed	-$189K	–	2844
2025 Q3	$189K	Buy	+3,945	New	+$87.5K	﹤0.01%	2353
2025 Q2	–	Sell	-3,639	Closed	-$63.4K	–	2883
2025 Q1	$63.4K	Hold	3,639	–	–	﹤0.01%	2665
2024 Q4	$139K	Hold	3,639	–	–	﹤0.01%	2476
2024 Q3	$122K	Buy	3,639 +2,050	+129%	+$86.3K	﹤0.01%	2551
2024 Q2	$53.8K	Buy	+1,589	New	+$87.8K	﹤0.01%	2749
2021 Q2	–	Sell	-206	Closed	-$97.7K	–	2461
2021 Q1	$97.7K	Hold	206	–	–	﹤0.01%	2252
2020 Q4	$363K	Sell	206 -54	-21%	-$71.3K	﹤0.01%	1647
2020 Q3	$250K	Hold	260	–	–	﹤0.01%	1727
2020 Q2	$302K	Buy	+260	New	+$235K	﹤0.01%	1648

Other funds holding KRRO

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

7IH

72 Investment Holdings Stamford, Connecticut $49.6M AUM 684.72% 1-Year Est. Return

MetLife Investment Management's KRRO Position: Q4 2025 in Review

MetLife Investment Management sold out of Korro Bio (KRRO) in Q4 2025, closing a stake of 3,945 shares — an estimated $189K sold.

MetLife Investment Management first reported a position in KRRO in Q2 2020 and held it in 9 quarters. The position peaked at $363K in Q4 2020. 83 funds tracked by Wall St. Rank hold KRRO as of Q4 2025.

MetLife Investment Management reported no remaining Korro Bio position as of Q4 2025 after selling out during the quarter.
MetLife Investment Management sold 3,945 Korro Bio shares in Q4 2025, an estimated $189K.
MetLife Investment Management first reported a position in Korro Bio in Q2 2020 and held it in 9 quarters.
MetLife Investment Management's Korro Bio position peaked at $363K in Q4 2020.
83 funds tracked by Wall St. Rank held Korro Bio as of Q4 2025.

Based on MetLife Investment Management's 13F filing for Q4 2025, filed 12 Feb 2026.